CAR T-cell treatment for hard-to-treat childhood tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent/guardian must sign consent (HIPAA authorization) to allow access to medical records
- Your child must be well enough to do daily activities (performance score at least 60) and expected to live at least 12 weeks
- Diagnosis must be confirmed as neuroblastoma/ganglioneuroblastoma, or osteosarcoma, using past tissue or bone marrow samples
- The cancer must be high-risk and either relapsed, refractory, or not responding to standard treatment, and must be measurable/evaluable on scans
- No major brain/CNS disease is known, and there must be no seizure condition needing anti-seizure medicines
- Not currently pregnant or breastfeeding, and no active ongoing second cancer needing treatment; also no past serious allergy to certain study medicines or mouse-based materials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.